Ask about this productRelated genes to: MYH10 Blocking Peptide
- Gene:
- MYH10 NIH gene
- Name:
- myosin heavy chain 10
- Previous symbol:
- -
- Synonyms:
- NMMHCB
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1991-05-15
- Date modifiied:
- 2016-10-05
Related products to: MYH10 Blocking Peptide
Related articles to: MYH10 Blocking Peptide
- Multiple myeloma (MM) remains an incurable hematological malignancy with heterogeneous outcomes, necessitating the identification of novel prognostic markers for improved patient stratification and treatment. - Source: PubMed
Publication date: 2026/07/16
Xu YuxiuSun XiaoliYang JingMa DongshengWan JiangweiLei TingtingWang Tao - The pronounced heterogeneity of bladder cancer (BLCA) drives divergent patient outcomes and therapy responses. Mitophagy, a pivotal cellular quality-control and metabolic mechanism, modulates the dynamics of the tumor microenvironment (TME). Its prognostic significance and potential for guiding precision oncology, however, remain incompletely defined. This investigation aimed to evaluate the translational utility of mitophagy-associated signatures for the risk stratification of BLCA, profiling of TME, and prediction of therapeutic response. - Source: PubMed
Publication date: 2026/06/25
Han ChenyuMiao LiuyangLiu YanWang YitianWu JiaxuanDu Peng - Superficial rearranged soft tissue tumors are rare mesenchymal neoplasms showing heterogenous morphology and clinical behavior. They usually present as slowly enlarging nodules in young adults and can mimic other spindle cell tumors. While some -altered mesenchymal neoplasms can be classified into defined WHO categories (e.g., inflammatory myofibroblastic tumor, epithelioid fibrous histiocytoma, and a few others), the nosology of many tumors has not yet been delineated, and they are currently reported descriptively. A case of a young man with a three-year follow-up is presented, providing prognostic insights into this entity. - Source: PubMed
Publication date: 2026/06/02
Kameh Khosh MasihWellenbrock SaschaKameh Khosh DanielHirsch TobiasAgaimy AbbasO'Dey Dan Mon - Fetal growth restriction (FGR) remains a major contributor to neonatal morbidity and mortality worldwide, with limited effective diagnostic and therapeutic options. To better understand its molecular mechanism, we performed integrated multi-omics analyses of placental tissues from FGR pregnancies and normal controls, identifying Ring Finger Protein 126 (RNF126), an E3 ubiquitin ligase, as a key regulator of FGR and a potential biomarker distinguishing FGR from small-for-gestational-age (SGA) fetuses. Placenta-specific RNF126 conditional knockout (cKO) mice demonstrated a causal role of elevated placental RNF126 in FGR development . Functional studies revealed that RNF126 induced endoplasmic reticulum (ER) stress and apoptosis in trophoblasts. Mechanistically, RNF126 promoted a ubiquitin-proteasome-mediated degradation of the MYH9/MYH10 complex, thereby exacerbating ER stress and impairing trophoblast function, with lysine 833 (K833) of MYH9 identified as a critical ubiquitination site. Collectively, these findings elucidate an RNF126-mediated pathogenic mechanism in FGR and highlight RNF126 as a promising biomarker and therapeutic target. - Source: PubMed
Publication date: 2026/06/08
Lu LilinYe XiaomeiLan JiawenXu ShuxiuCheng ManyuLv ChenlinZhou JunLi Jing - Spindle cell tumors with rearrangements exhibit variable clinical behaviors, ranging from benign to highly aggressive malignancies. The underlying heterogeneity is suspected to be associated with distinct fusion partner genes. Understanding the impact of these fusion partners on oncogenic potential is crucial for precision therapy. - Source: PubMed
Publication date: 2026/06/04
Gui QiZhang YingYang MeiLiang RongruiHuang ManYang XiaoshanChen NanChen XiaojunWu MengyaoChen HuafeiMeng LijunXiao ShengTao Min